SUPPORTING INFORMATION

General Information:

All reactions were performed under an Ar atmosphere with stirring. The (*R*,*R*)-Ph-box ligand (2) and the 2,2'-methylenebis[(4*R*,5*S*)-4,5-diphenyl-2-oxazoline (**S-1**) were purchased from Aldrich. All other reagents were purchased from Aldrich or Acros. The MnO₂ used is <5 micron, 85%, from Aldrich. Solvents were purified using a solvent filtration system purchased from Contour Glass Co (Irvine, California). ¹H NMR spectra were recorded at 400 or 500 MHz using Varian instruments. ¹³C NMR data were recorded at 75.5 MHz. Coupling constants (*J*) are in hertz. Abbreviations used are s = singlet, d = doublet, t = triplet, m = multiplet, bs = broad singlet, and dd = doublet of doublets, td = triplet of doublets, qd = quartet of doublets. IR spectra were taken neat using a Nicolet-Impact 420 FTIR. Wave numbers in cm⁻¹ are reported for characteristic peaks. High resolution mass spectra were obtained at SUNY, Buffalo's mass spec. facility on a ThermoFinnigan MAT XL spectrometer. Optical rotations were obtained using a JASCO P-2000 Polarimeter fitted with a micro cell with a 1 dm path length. Enantiomeric excess was determined by high-performance liquid chromatography (HPLC) using, Chiralpak AD-RH or Regis (*S*,*S*) Whelk-O 1 chiral analytical column (UV detection at 254 nm). Melting points were obtained on an electrothermal melting point apparatus and are reported uncorrected.

Synthesis of Ligand:



2,2-Bis{2-[4(R),5(S)-diphenyl-1,3-oxazolinyl]}propane (3)¹

Alkylation of S-1 was conducted following a procedure used by Denmark for similar substrates.² 2,2'-Methylenebis[(4R,5S)-4,5-diphenyl-2-oxazoline] (S-1) (1.00 g, 2.18 mmol) was dissolved in dry THF (67 mL) under an argon atmosphere. To this solution, diisopropylamine (0.31 mL, 0.22 g, 2.19 mmol) and N,N,N,N-tetramethylethylenediamine (0.66 mL, 0.51 g, 4.40 mmol) were added via syringe. The solution was then cooled to -70 °C in a 2-propanol/dry ice bath. Once cooled, n-butyl lithium (2.73 mL, 4.40 mmol, 1.6 M solution in hexanes), was added dropwise. After the addition the reaction mixture was warmed to -20 °C and allowed to stir for 30 min. The mixture was then cooled to -70 °C and iodomethane (0.28 mL, 0.64 g, 4.49 mmol) was added via syringe. The cold bath was removed and the reaction was allowed to proceed for an additional 16 h at rt. The reaction mixture was guenched with sat. NH₄Cl (aq.) (75 mL) and then diluted with water (50 mL). The mixture was extracted with Et₂O (3 x 100 mL) and the combined organic layers were dried over MgSO₄, filtered, and the solvent was removed in vacuo. Flash chromatography of the resulting crude solid on SiO₂ (50% v/v EtOAc in hexanes) afforded the (4R,5S)-di-Ph-box ligand 3 (1.04 g, 2.14 mmol) in 89% yield. ¹H NMR (400 MHz, CDCl₃): δ 7.02 (s, 10H), 6.96 (s, 10H), 5.97 (d, 10.0 Hz, 2H), 5.59 (d, 10.4 Hz, 2H), 1.92 (s, 6H) ¹³C NMR (75.5 MHz, CDCl₃): § 170.4, 137.5, 136.2, 127.9, 127.6, 127.4 (2 signals overlapped), 126.9, 126.6, 86.3, 73.8, 39.6, 24.8; IR (neat): 3029, 2924, 1656, 1496, 1454, 1143, 1114, 975, 697 cm⁻¹; HRMS (ESI) calcd for [M+H]⁺ C₃₃H₃₁O₂N₂ 487.2380, found 487.2374.

Synthesis of arylsulfonylchoride:



3,5-Di-*tert*-butylbenzenesulfonyl chloride (S-3)³

The known sulforyl chloride **S-3** was synthesized as reported by Huntress.³

3,5-Di-*tert*-butylbenzene (0.58 mL, 0.50 g, 2.6 mmol) was dissolved in CHCl₃ (2.5 mL) at 0 °C with stirring. To the solution chlorosulfonic acid (2.45 mL, 4.29 g, 36.8 mmol) was added cautiously, dropwise, and the solution was allowed to stir for 30 min. The reaction was warmed to rt and allowed to stir for an additional 30 min. The mixture was then poured over crushed ice and the organic layer separated. The aqueous layer was then extracted with CHCl₃ (2 x 10 mL), and the organics were pooled. The combined organics were washed with cold water (25 mL), dried over Na₂SO₄, filtered, and the solvent removed *in vacuo*. Flash chromatography of the resulting crude solid on SiO₂ (0-20% v/v CH₂Cl₂ in hexanes gradient) afforded 3,5-di-*tert*-butylbenzenesulfonyl chloride (**S-3**) in 53% yield (unoptimized). ¹H NMR (400 MHz, CDCl₃): δ 7.84 (s, 2H), 7.78 (s, 1H), 1.38 (s, 18H).

Synthesis of 2-allylaniline substrates:



o-OMe, 1h Muniz.⁷ In this procedure the desired aniline is first alkylated via the $S_N 2$ reaction of the aniline and allyl bromide. The N-allylaniline is then converted to the o-allylaniline via a 3.3'-sigmatropic rearrangement, facilitated by BF₃·Et₂O, in a sealed vessel at 180°C. Lastly, the o-allylaniline was sulforvlated by treatment with the desired sulforvl chloride under basic conditions. N-(2-Allyl-phenyl)-4-methyl-benzenesulfonamide $(1a)^5$ was obtained from tosylation of 2-allylaniline.⁸ N-(2-Allyl-4-methylphenyl)-4-methyl-benzenesulfonamide $(1b)^6$ was obtained from tosylation of 4-methyl-2-allylaniline. N- $(2-Allyl-4-cyano-phenyl)-4-methyl-benzenesulfonamide (1c)^4$ was obtained from tosylation of 4-cyano-2-N-(2-Allyl-4-fluoro-phenyl)-4-methyl-benzenesulfonamide (1d)⁶ was obtained from allylaniline.⁷ tosylation of 4-fluoro-2-allylaniline. N-(2-Allyl-4-chloro-phenyl)-4-methyl-benzenesulfonamide (1e)⁶ was obtained by tosylation of 2-allyl-4-chloro-phenylamine.⁷ N-(2-Allyl-4-methoxy-phenyl)-4-methylbenzenesulfonamide $(1f)^6$ was obtained from tosylation of 4-methoxy-2-allylaniline. N-(2-Allyl-5methoxy-phenyl)-4-methyl-benzenesulfonamide $(1g)^4$ was obtained from tosylation of 5-methoxy-2allylaniline.⁹ N-(2-Allyl-phenyl)-4-nitro-benzenesulfonamide¹⁰ (1) was synthesized as previously reported from the sulfonylation of 2-allylaniline.⁶ N-(2-Allyl-phenyl)-methyl-sulfonamide (1k)⁵ was synthesized as previously reported from the sulfonvlation of 2-allylaniline.⁶

N-(2-Allyl-6-methoxy-phenyl)-4-methyl-benzenesulfonamide (1h)

The sulfonamide **1h** (0.3200 g, 1.01 mmol) was obtained in 76% yield from tosylation of 6-methoxy-2allylaniline¹¹ (0.2179 g, 1.34 mmol). mp = 117-119 °C; ¹H NMR (500 MHz, CDCl₃): δ 7.49 (d, J = 8.0 Hz, 2H), 7.18-7.11 (m, 3H), 6.89 (d, J = 8.0 Hz, 1H), 6.48 (d, J = 8.5 Hz, 1H), 6.20 (s, 1H), 5.98-5.93 (m, 1H), 5.14-5.07 (m, 2H), 3.74 (d, J = 6.5 Hz, 2H), 3.15 (s, 3H), 2.38 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 154.2, 143.1, 140.9, 136.9, 136.7, 128.7, 128.1, 127.5, 122.8, 122.3, 116.1, 108.1, 54.7, 35.8, 21.4; IR (neat): 3274, 3076, 2973, 1640, 1590, 1473, 1333, 1272, 1162, 1080, 911 cm⁻¹; HRMS (ESI) calcd for [M+1]⁺C₁₇H₂₀O₃NS 318.1158, found 318.1152.



N-(2-allylphenyl)benzene sulfonamide (1i)

The procedure for the synthesis of substrate **1i** was the same as stated above except that the solution was treated with benzenesulfonyl chloride. Sulfonamide **1i** (1.40 g, 5.00 mmol) was obtained from sulfonylation of 2-allylaniline⁸ (1.00 g, 7.50 mmol) as a light brown solid in 66% yield (unoptimized). mp = 84-85 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.72-7.70 (m, 2H), 7.57-7.54 (m, 1H), 7.46-7.41 (m, 3H), 7.24-7.20 (m, 1H), 7.15-7.11 (m, 1H), 7.07 (d, J = 8.0 Hz, 1H), 6.53 (bs, 1H), 5.81-5.73 (m, 1H), 5.11 (dd, J = 1.2, 10.0 Hz, 1H), 4.94 (dd, J = 1.6, 17.2 Hz, 1H), 2.98 (d, J = 6.4 Hz, 2H); ¹³C NMR (75.5 MHz, CDCl₃): δ 139.7, 135.6, 134.8, 132.9, 132.2, 130.5, 129.0, 127.7, 127.0, 126.5, 124.7, 117.1, 36.1; IR (neat): 3281, 3067, 2913, 1637, 1583, 1491, 1447, 1393, 1330, 1162, 1091, 918 cm⁻¹; HRMS (ESI) calcd for [M+1]⁺C₁₅H₁₆O₂NS 274.0896, found 274.0899.



N-(2-allylphenyl)-2-(trimethylsilyl)ethane sulfonamide (11)

The procedure for the synthesis of substrate **11** was the same as stated above except that the solution was treated with 2-(trimethylsilyl)ethanesulfonyl chloride. Sulfonamide **11** (0.30 g, 1.00 mmol) was obtained from sulfonylation of 2-allylaniline⁸ (0.25 g, 1.90 mmol) as a dark red oil in 55% yield (unoptimized). ¹H NMR (400 MHz, CDCl₃): δ 7.47 (d, J = 7.6 Hz, 1H), 7.26-7.20 (m, 2H), 7.15 (d, J = 7.2 Hz, 1H), 6.28 (bs, 1H), 6.01-5.91 (m, 1H), 5.19 (dd, J = 1.6, 10.0 Hz, 1H), 5.09 (dd, J = 1.6, 17.2 Hz, 1H), 3.44 (d, J = 5.6 Hz, 2H), 3.07-3.03 (m, 2H), 1.07-1.03 (m, 2H), 0.01 (s, 9H); ¹³C NMR (75.5 MHz, CDCl₃): δ 135.6, 135.4, 130.8, 127.8, 125.6, 123.5, 122.0, 117.1, 48.7, 36.3, 10.4, -2.1; IR (neat): 3279, 3077, 2954, 1638, 1585, 1494, 1407, 1330, 1252, 1148, 918, 860, 840, 754, 698 cm⁻¹; HRMS (ESI) calcd for [M+Na]⁺ C₁₄H₂₃O₂NSSiNa 320.1111, found 320.1115.



N-(2-allylphenyl)-3,5-di-*tert*-butylbenzenesulfonamide (1m)

The procedure for the synthesis of substrate **1m** was the same as stated above except that the solution was treated with 3,5-di-*tert*-butylbenzenesulfonyl chloride³ and the reaction time was prolonged to 48 h. Sulfonamide **1m** (0.36 g, 0.93 mmol) was obtained from sulfonylation of 2-allylaniline⁸ (0.14 g, 1.04 mmol) as a pale brown solid in 90% yield. mp = 132 – 133 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.57 (s, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.44 (s, 1H), 7.27-7.24 (m, 2H), 7.13 (t, J = 7.2 Hz, 1H), 7.02 (d, J = 8.0 Hz, 1H), 6.41 (bs, 1H), 5.67-5.63 (m, 1H), 5.07 (dd, J = 1.6, 10.0 Hz, 1H), 4.88 (dd, J = 1.2, 17.2 Hz, 1H), 2.74 (d, J = 6.0 Hz, 2H), 1.23 (s, 18H); ¹³C NMR (75.5 MHz, CDCl₃): δ 152.1, 138.5, 135.5, 135.2, 132.5, 130.3, 127.8, 126.8, 126.6, 125.7, 121.1, 117.0, 35.9, 35.1, 31.1; IR (neat): 3266, 3076, 2958, 1596, 1483, 1333, 1166 cm⁻¹; HRMS (ESI) calcd for [M+1]⁺C₂₃H₃₂O₂NS 386.2148, found 386.2141.

Synthesis of 4-pentenylsulfonamide substrates:

$$\begin{array}{c} R \\ R \end{array} \xrightarrow{\text{IDA, Br}} R \\ R \\ R \\ \hline \text{THF, -78 °G+ rt, 24 h} \\ R \\ \hline \text{R} \\ \hline \text{R} \\ \hline \text{O °C+ rt, 24 h} \\ \hline \text{R} \\ \hline \text{NH}_2 \\ \hline \begin{array}{c} Pyr, RSO_2CI, CH_2CI_2 \\ \hline \text{O °C+ rt, 24 h} \\ \hline \text{O °C+ rt, 24 h} \\ \hline \text{SO}_2R \\ \hline \end{array}$$

Substrates **7a-d**, **11**¹²⁻¹⁵ were synthesized according to the procedures previously reported by Bender and Tamaru.¹²⁻¹⁵ *N*-(2, 2-Dimethyl-pent-4-enyl)-4-methyl-benzenesulfonamide (**7a**)¹² was obtained from sulfonylation of 2,2-dimethyl-pent-4-enyl)-methyl-sulfonamide (**7b**)¹⁶ was obtained from sulfonylation of 2,2-dimethyl-pent-4-enyl)-methyl-sulfonamide (**7b**)¹⁶ was obtained from sulfonylation of 2,2-dimethyl-pent-4-enyl)-methyl-sulfonamide (**7c**)¹⁷ was obtained from sulfonylation of 2,2-dimethyl-pent-4-enyl)-4-nitro-benzenesulfonamide (**7c**)¹⁷ was obtained from sulfonylation of 2,2-dimethyl-pent-4-enyl-4-nitro-benzenesulfonamide (**7c**)¹⁷ was obtained from sulfonylation of 2,2-dimethyl-pent-4-enylamine¹³ with 4-nitro-benzenesulfonyl chloride. *N*-(2, 2-Diphenyl-pent-4-enyl)-4-methyl-benzenesulfonamide (**7d**)¹⁴ was obtained from sulfonylation of 2,2-diphenyl-pent-4-enylamine¹³ with tosyl chloride. *N*-(2,2,4-trimethyl-pent-4-enyl)- 4-Methyl-benzenesulfonamide (**11**)¹⁵ was obtained from sulfonylation of 2,2,4-trimethyl-pent-4-enylamine with tosyl chloride. *N*-(5-allyl-2,2-di-tert-butyl-[1,3,2]dioxasilinan-5-ylmethyl)-4-methyl-benzenesulfonamide (**7g**)⁴ was synthesized by the procedure previously reported by Fuller.⁴ *N*-(Pent-4-enyl)-4-methyl-benzenesulfonamide (**7e**)⁵ was obtained from the stille coupling of *N*-(2-allylbenzyl)-4-methylbenzenesulfonamide (**13**)⁵ was obtained from the Stille coupling of *N*-(2-bromobenzyl)-4-methylbenzenesulfonamide with allyltributyltin as previously reported.⁵



N-(3,3-dimethylpent-4-enyl)-4-methylbenzenesulfonamide (9) was synthesized according to the procedure previously reported by Haque.^{18,19}

1,1,1,3,3,3-Hexamethyldisilizane (1.86 mL, 1.41 g, 8.80 mmol) was dissolved in dry THF (20 mL) and cooled to -78 °C under an Argon atmosphere. To this solution n-Butyl lithium (3.5 mL, 2.5 M solution in hexanes), was added dropwise and the solution was allowed to stir for 20 minutes. A solution of 1-tosylpyrrolidin-2-one¹⁸ (1.00 g, 4.20 mmol) in dry THF (20 mL) was added dropwise and the solution was allowed to stir for an additional 20 min. Next, iodomethane (0.55 mL, 1.25 g, 8.80 mmol) was added dropwise to the reaction and the resulting mixture was then left to stir and come to rt over 24 h. The reaction was quenched with 40 mL of water and extracted with 4 x 30 mL of EtOAc. The combined organics were washed with brine (2 x 60 mL), dried over Na₂SO₄, filtered, and the solvent removed *in vacuo*. The resulting crude solid (0.998 g) was used without further purification.

The crude 3,3-dimethyl-1-tosylpyrrolidin-2-one (0.998 g, 3.70 mmol) was dissolved in dry toluene (37 mL) and cooled to -78 °C under an Argon atmosphere. To this mixture DIBAL-H (6.87 mL, 1.2 M solution in toluene, 8.20 mmol), was added dropwise with stirring and the reaction was allowed to continue for 2 h. The reaction was quenched with 60 mL of sat. sodium potassium tartrate (aq.) and then left to stir at rt for 24 h. The organic layer was separated and the aqueous layer was then extracted with EtOAc (3 x 30 mL). The combined organics were dried over Na₂SO₄, filtered, and the solvent removed *in vacuo*. The resulting crude material (1.01 g) was used without further purification.

A solution of MePPh₃Br (3.30 g, 9.20 mmol) in dry THF (10 mL) was prepared and cooled to 0 °C under an Argon atmosphere. To this solution KO^tBu (1.05 g, 9.20 mmol) was added in two portions and the mixture was allowed to stir for 10 min. The crude 3,3-dimethyl-1-tosylpyrrolidin-2-ol (1.01 g, 3.70 mmol) dissolved in dry THF (20 mL), was added dropwise and the resulting mixture was then left to stir and come to rt over 24 h. The reaction was quenched with 35 mL of water and the organic layer was separated. The aqueous layer was then extracted with EtOAc (3 x 30 mL) and the combined organics were dried over Na₂SO₄, filtered, and the solvent removed *in vacuo*. Flash chromatography of the resulting crude oil on SiO₂ (0-30% v/v EtOAc in hexanes gradient) afforded the known sulfonamide (0.75 g, 2.80 mmol) (**9**)¹⁹ in 67% yield over 3 steps (unoptimized). ¹H NMR (400 MHz, CDCl₃): δ 7.73 (d, J = 8.0 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 5.68 (dd, J = 10.8, 17.2 Hz, 1H), 4.93 (d, J = 11.2 Hz, 1H), 4.87 (d, J = 18.4 Hz, 1H), 4.25 (bs, 1H), 2.94-2.87 (m, 2H), 2.43 (s, 3H), 1.47 (apparent t, J = 8.0 Hz, 2H), 0.94 (s, 6H).



N-(3-allyl-3-vinylhex-5-enyl)-4-methylbenzenesulfonamide (15)

The sulfonamide **15** was prepared the same as above except allyl bromide was used in place of methyl iodide for the alkylation. The desired sulfonamide **15** was obtained in 51% yield over 3 steps. ¹H NMR (500 MHz, CDCl₃): δ 7.72 (d, J = 8.5 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 5.67-5.58 (m, 3H), 5.10-4.86 (m, 6H), 4.32 (t, J = 6.0 Hz, 1H), 2.93-2.89 (m, 2H), 2,43 (s, 3H), 2.02 (d, J = 7.5 Hz, 4H), 1.47 (dd, J = 8.0, 9.5 Hz, 2H); ¹³C NMR (75.5 MHz, CDCl₃): δ 144.3, 143.4, 136.9, 133.7, 129.7, 127.1, 117.9, 113.8, 41.3, 40.7, 38.9, 36.5, 21.5; IR (neat): 3282, 3076, 2977, 2923, 1639, 1599, 1418, 1327, 1160, 1095, 999, 915, 815 cm⁻¹; HRMS (ESI) calcd for [M+1]⁺C₁₈H₂₆O₂NS 320.1679, found 320.1680.



3,5-Di*tert***-butyl**-*N***-(pent-4-enyl)benzenesulfonamide (7f)** was synthesized analogous to the protocol developed by Marcotullio.²⁰

Sulfonamide S-4 was synthesized following the analogous procedure described by Flemer.²¹

To an oven dried flask with a stir bar, under argon, was added 3,5-di-*tert*-butylbenzenesulfonyl chloride (**S-3**) (0.8 g, 2.76 mmol) and methylene chloride (15 mL) and the flask was placed in a 0 °C ice bath. Gaseous ammonia was introduced through a needle inlet such that it bubbled through the reaction mixture at a steady flow. With a steady flow of ammonia the reaction mixture was allowed to stir at 0 °C, under argon for 30 minutes. After the time had elapsed the reaction mixture was diluted with brine and extracted with methylene chloride (3 x 15 mL). The organic extracts were combined, dried over Na₂SO₄, filtered, and the solvent removed *in vacuo* providing the crude sulfonamide **S-4** ~0.8 g, which was used without further purification. mp = 145 – 146 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.77 (d, J = 1.6 Hz, 2H), 7.63 (t, J = 1.6 Hz, 1H), 4.88 (bs, 2H), 1.35 (s, 18H); ¹³C NMR (75.5 MHz, CDCl₃): δ 152.3, 141.3, 127.1, 120.5, 35.2, 31.3; IR (neat): 3342, 3260, 2960, 1599, 1551, 1475, 1336, 1311, 1248, 1169, 904, 734 cm⁻¹; HRMS (ESI) calcd for [M+Na]⁺ C₁₄H₂₃O₂NSNa 292.1342 found 292.1341.

To a stirred solution of pent-4-en-1-ol (0.6 mL 0.5 g, 5.81 mmol) and MsCl (0.54 mL, 0.799 g, 6.98 mmol) in CH₂Cl₂ (30 mL), at 0 °C, Et₃N (2.45 mL, 1.779 g, 17.57 mmol) was added dropwise. After 1 h

the reaction mixture was diluted with H_2O (40 mL) and extracted with CH_2Cl_2 (3 × 25 mL). The combined organic layers were washed with H_2O (2 × 50 mL), brine (2 × 50 mL), dried over Na₂SO₄, filtered, and the solvent removed *in vacuo* providing the crude mesylate, 0.96 g, which was used in the next step without further purification.

Potassium carbonate (0.77 g, 5.57 mmol) was dissolved in DMF (9 mL) at 120 °C and 3,5-di-*tert*butylbenzenesulfonamide **S-4** (0.75 g, 2.78 mmol) was added to the resulting solution. After 30 min a solution of the mesylate (0.304 g, 1.85 mmol) in DMF (1 mL) was added. After 1 h the reaction mixture was cooled, diluted with H₂O (10 mL) and extracted with Et₂O (4 × 5 mL). The combined organic layers were washed with H₂O (3 × 5 mL), brine (3 × 5 mL), dried over MgSO₄, filtered, and the solvent was removed *in vacuo*. The crude residue was further purified via flash chromatography on SiO₂ (0-40% Et₂O in hexanes eluent) providing pure 3,5-di-*tert*-butyl-*N*-(pent-4-enyl)benzenesulfonamide (**7f**), (0.46 g, 1.36 mmol) in 70% yield over two steps as a viscous clear oil. ¹H NMR (400 MHz, CDCl₃): δ 7.69 (d, J = 2.0 Hz, 2H), 7.62 (t, J = 2.0 Hz, 1H), 5.73-5.63 (m, 1H), 4.97-4.92 (m, 2H), 4.40 (t, J = 6.0 Hz, 1H), 2.99 (q, J = 6.8 Hz, 2H), 2.04 (qd, J = 1.2, 7.2 Hz, 2H), 1.60-1.52 (m, 2H), 1.35 (s, 18H); ¹³C NMR (75.5 MHz, CDCl₃): δ 152.1, 139.2, 137.2, 126.7, 121.1, 115.5, 42.6, 35.1, 31.2, 30.6, 28.6; IR (neat): 3279, 3020, 2964, 1600, 1439, 1328, 1311, 1248, 1163, 883, 703 cm⁻¹; HRMS (ESI) calcd for [M+Na]⁺ C₁₉H₃₁O₂NSNa 360.1968, found 360.1970.

Catalytic Methods for Aniline Substrates:

Representative procedure for the catalytic racemic aminohalogenation of alkenes:



(±)-2-(Iodomethyl)-1-tosylindoline (4a)

Copper (II) triflate (13.0 mg, 0.036 mmol) was added to an oven dried pressure tube (10 mL) equipped with a stir bar, in a glovebox. Upon removal from the glove box the pressure tube was flushed with argon any time it was opened. To the tube, dipyridyl (7.10 mg, 0.045 mmol) was added and the mixture was dissolved in PhCF₃ (1.80 mL), the tube was then sealed and heated to 60 °C for 2 h in an oil bath with stirring. Upon cooling to rt, the following reagents were then added sequentially: sulfonamide (**1a**) (51.2 mg, 0.178 mmol), MnO₂ (46.9 mg, 0.539 mmol), K₂CO₃ (24.9 mg, 0.180 mmol), ⁱPr-I (0.108 mL, 183.6 mg, 1.08 mmol) and ~36 mg of flame activated 4Å molecular sieves. The tube was then flushed with argon, sealed, and sonicated to ensure that all reagents were in solution. The mixture was stirred at 120 °C (oil bath) for 16 h. The room temperature reaction mixture was then filtered through a pad of Celite with EtOAc. The filtrate was collected and the solvent removed *in vacou* to yield the crude product as a solid. Flash chromatography of the resulting crude material on SiO₂ (0-20% v/v EtOAc in hexanes, isocratic, was used prior to chiral HPLC analysis.

Representative procedure for the catalytic enantioselective aminohalogenation of aniline derived alkenes:



(S)-2-(Iodomethyl)-1-tosylindoline (4a)

Copper (II) triflate (12.5 mg, 0.035 mmol) was added to an oven dried pressure tube (10 mL) equipped with a stir bar, in a glovebox. Upon removal from the glove box the pressure tube was flushed with argon any time it was opened. To the tube, (*R*,*R*)-Ph-box (2) (14.5 mg, 0.045 mmol) in PhCF₃ (0.54 mL, 0.08 M) was added and the mixture was dissolved in additional PhCF₃ (1.21 mL). The tube was sealed and the mixture was stirred at 60 °C (oil bath) for 2 h. Upon cooling to rt, the following reagents were added

sequentially: N-(2-allylphenyl)-4-methyl-benzenesulfonamide⁵ (1a) (50.7 mg, 0.176 mmol), MnO₂ (47.7 mg, 0.549 mmol), K₂CO₃ (24.5 mg, 0.177 mmol), ¹Pr-I (0.104 mL, 177.5 mg, 1.04 mmol) and ~36 mg of flame activated 4Å molecular sieves. The tube was then flushed with argon, sealed, and the mixture was sonicated to ensure that all reagents were in solution. The reaction mixture was then stirred at 105 °C (oil bath) for 6 h. Upon cooling to rt, the mixture was filtered through a pad of Celite with EtOAc. The filtrate was collected and the solvent was removed *in vacou* to yield the crude product as a solid. Flash chromatography of the resulting crude material on SiO₂ (0-20% v/v EtOAc in hexanes gradient) afforded indoline 4a (62.7 mg, 0.152 mmol) as opaque crystals in 86% yield. Further purification by HPLC 10% EtOAc in hexanes, isocratic, was used prior to chiral HPLC analysis. mp = 123-125 °C; $[\alpha]_D^{24} = 49.2$ ° (c = 0.5, CHCl₃), ee = 89%, determined by HPLC analysis [Regis (S,S) Whelk-O 1, 2% IPA/hexane, 1 mL/min, $\lambda = 254$ nm, t(major) = 14.92 min, t(minor) = 18.83 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.65 (d, J = 8.0 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.25-7.18 (m, 3H), 7.06-7.03 (m, 2H), 4.37-4.35 (m, 1H), 7.06-7.03 (m, 2H), 7.3.67 (dd, J = 3.6, 9.6 Hz, 1H), 3.27 (apparent t, J = 10.0 Hz, 1H), 2.95-2.84 (m, 2H), 2.36 (s, 3H); ^{13}C NMR (75.5 MHz, CDCl₃): δ 144.2, 141.2, 134.5, 130.4, 129.7, 128.0, 127.0, 125.2, 124.9, 116.8, 62.5, 34.8, 21.5, 11.4; IR (neat): 3032, 2916, 1597, 1479, 1355, 1167, 1013, 961, 757, 666 cm⁻¹; HRMS (EI) calcd for $[M]^+$ C₁₆H₁₆O₂NIS 412.9941, found 412.9939.

Assignment of Absolute Stereochemistry of Indoline Products:

The crystal structure of indoline **4a** (CCDC 858586) showing the S stereochemistry was obtained by William W. Brennessel at the University of Rochester. The absolute configuration of all other indoline products was assigned by analogy to this structure.



2-Isobutyl-1-tosylindoline (6)

In a duplicate run, Indoline **6** (4.2 mg, 0.013 mmol) was obtained as a clear oil in 7% yield, as a minor product, from the corresponding sulfonamide **1a**⁵ (51.9 mg, 0.181 mmol): ¹H NMR (400 MHz, CDCl₃): δ 7.66 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 8.4 Hz, 2H), 7.23-7.19 (m, 2H), 7.14 (d, J = 8.4 Hz, 2H), 7.02 (d, J = 5.2 Hz, 1H), 4.30-4.25 (m, 1H), 2.67 (dd, J = 9.6, 16.4 Hz, 1H), 2.40 (dd, J = 1.6, 15.6 Hz, 1H), 2.35 (s, 3H), 1.89-1.83 (m, 1H), 1.76-1.69 (m, 1H), 1.39-1.32 (m, 1H), 0.98 (dd, J = 6.4, 20.8 Hz, 6H); ¹³C NMR

(75.5 MHz, CDCl₃): δ 143.6, 141.3, 135.4, 132.9, 129.4, 127.6, 127.0, 125.1, 124.9, 118.5, 61.2, 45.7, 34.5, 24.4, 22.8, 22.4, 21.5; IR (neat): 3031, 2955, 1677, 1592, 1479, 1456, 1353, 1167, 1091, 758 cm⁻¹; HRMS (ESI) calcd for [M+Na]⁺C₁₉H₂₃O₂NSNa 352.1342, found 352.1343.



(S)-2-(Iodomethyl)-5-methyl-1-tosylindoline (4b)

Indoline **4b** (62.9 mg, 0.147 mmol) was obtained as a white solid in an 85% yield from the corresponding sulfonamide⁶ **1b** (52.2 mg, 0.173 mmol): mp = 74-75°C; $[\alpha]_D^{24} = 65.8$ ° (c = 0.5, CHCl₃), ee = 90%, determined by HPLC analysis [Regis (*S*,*S*) Whelk-O 1, 2% IPA/hexane, 1 mL/min, $\lambda = 254$ nm, t(major) = 12.96 min, t(minor) = 16.02 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.53 (m, 3H), 7.18 (d, J = 8.0 Hz, 2H), 7.02 (d, J = 8.0 Hz, 1H), 6.86 (s, 1H), 4.34-4.31 (m,1H), 3.65 (dd, J = 4.0, 10.0 Hz, 1H), 3.25 (apparent t, J = 10.0 Hz, 1H), 2.90-2.78 (m, 2H), 2.36 (s, 3H), 2.28 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 144.1, 138.8, 134.7, 134.5, 130.5, 129.7, 128.6, 127.1, 125.8, 116.7, 62.7, 34.7, 21.5, 21.0, 11.4; IR (neat): 3029, 2919, 1597, 1486, 1354, 1166, 1090, 1024, 963, 814, 754, 666, 608 cm⁻¹; HRMS (ESI) calcd for [M+1]⁺ C₁₇H₁₉O₂NIS 428.0176, found 428.0189.



(S)-2-(Iodomethyl)-1-tosylindoline-5-carbonitrile (4c)

Indoline **4c** (63.7 mg, 0.145 mmol) was obtained as white crystals in 85% yield from *N*-(2-Allyl-4cyano-phenyl)-4-methyl-benzenesulfonamide (**1c**)⁴(53.4 mg, 0.171 mmol). mp = 151-153°C; $[\alpha]_D^{24} =$ 107.1° (c = 0.5, CHCl₃), ee = 84%, determined by HPLC analysis [Chiralpak AD-RH, 4% IPA/hexane, 1 mL/min, $\lambda = 254$ nm, t(minor) = 26.83 min, t(major) = 35.90 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.71 (d, J = 8.0 Hz, 1H), 7.61 (d, J = 8.8 Hz, 2H), 7.52 (d, J = 8.0 Hz, 1H), 7.34 (s, 1H), 7.25 (d, J = 8.0 Hz, 2H), 4.41-4.37 (m, 1H), 3.67 (dd, J = 3.2, 10.0 Hz, 1H), 3.34 (apparent t, J = 10.0 Hz, 1H), 3.06 (dd, J = 9.6, 12.8 Hz, 1H), 2.91 (dd, J = 3.2 Hz, 12.0 Hz, 1H), 2.39 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 145.3, 145.1, 134.3, 132.9, 131.2, 130.1, 128.9, 126.9, 118.7, 116.2, 107.8, 62.5, 34.7, 21.6, 11.0; IR (neat): 3022, 2923, 2226, 1607, 1482, 1359, 1167, 1090, 963, 814, 752, 666 cm⁻¹; HRMS (EI) calcd for [M]⁺ C₁₇H₁₅O₂NIS 437.9893, found 437.9887.



(S)-5-Fluoro-2-(iodomethyl)-1-tosylindoline (4d)

Indoline **4d** (64.3 mg, 0.149 mmol) was obtained as a white solid in an 80% yield from the corresponding sulfonamide⁶ **1d** (57.6 mg, 0.189 mmol). mp = 118-120°C; $[\alpha]_D^{24} = 43.9^\circ$ (c = 0.5, CHCl₃), ee = 89%, determined by HPLC analysis [Regis (*S*,*S*) Whelk-O 1, 2% IPA/hexane, 1 mL/min, λ = 254 nm, t(major) = 14.21 min, t(minor) = 16.80 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.61-7.58 (m, 1H), 7.53 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 6.92 (t, J = 8.8 Hz, 1H), 6.77(d, J = 8.0 Hz, 1H), 4.38-4.32 (m, 1H), 3.63 (dd, J = 3.2, 10.0 Hz, 1H), 3.26 (t, J = 10.0 Hz, 1H), 2.86-2.80 (m, 2H), 2.37 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 160.4 (d, J = 243.1 Hz), 144.4, 137.2, 134.1, 132.7 (d, J = 9.2 Hz), 129.8, 127.1, 118.1 (d, J = 243.1 Hz), 144.4, 137.2, 134.1, 132.7 (d, J = 9.2 Hz), 129.8, 127.1, 118.1 (d, J = 243.1 Hz), 144.4, 137.2, 134.1, 132.7 (d, J = 9.2 Hz), 129.8, 127.1, 118.1 (d, J = 243.1 Hz), 144.4, 137.2, 134.1, 132.7 (d, J = 9.2 Hz), 129.8, 127.1, 118.1 (d, J = 243.1 Hz), 144.4, 137.2, 134.1, 132.7 (d, J = 9.2 Hz), 129.8, 127.1, 118.1 (d, J = 243.1 Hz), 144.4, 137.2, 134.1, 132.7 (d, J = 9.2 Hz), 129.8, 127.1, 118.1 (d, J = 243.1 Hz), 144.4, 137.2, 134.1, 132.7 (d, J = 9.2 Hz), 129.8, 127.1, 118.1 (d, J = 243.1 Hz), 144.4, 137.2, 134.1, 132.7 (d, J = 9.2 Hz), 129.8, 127.1, 118.1 (d, J = 243.1 Hz), 144.4, 137.2, 134.1, 132.7 (d, J = 9.2 Hz), 129.8, 127.1, 118.1 (d, J = 243.1 Hz), 144.4, 137.2, 134.1, 132.7 (d, J = 9.2 Hz), 129.8, 127.1, 118.1 (d, J = 243.1 Hz), 144.4, 137.2, 134.1, 132.7 (d, J = 9.2 Hz), 129.8, 127.1, 118.1 (d, J = 243.1 Hz), 144.4, 137.2, 134.1, 132.7 (d, J = 9.2 Hz), 129.8, 127.1, 118.1 (d, J = 243.1 Hz), 144.4, 137.2, 134.1, 132.7 (d, J = 9.2 Hz), 129.8, 127.1, 118.1 (d, J = 243.1 Hz), 144.4, 137.2, 134.1, 132.7 (d, J = 9.2 Hz), 129.8, 127.1, 118.1 (d, J = 243.1 Hz), 144.4, 137.2, 134.1, 132.7 (d, J = 9.2 Hz), 129.8, 127.1, 118.1 (d, J = 10.1 Hz), 144.1 Hz), 144.1 Hz = 10.1 H

J = 8.1 Hz), 114.7 (d, J = 23 Hz), 112.3 (d, J = 24 Hz), 62.9, 34.8, 21.5, 10.9; IR (neat): 3031, 2921, 1598, 1481, 1356, 1166, 1090, 934, 814, 755, 667 cm⁻¹; HRMS (EI) calcd for $[M]^+ C_{16}H_{15}O_2NISF$ 430.9847, found 430.9837.



(S)-5-Chloro-2-(iodomethyl)-1-tosylindoline (4e)

Indoline **4e** (59.9 mg, 0.134 mmol) was obtained as a white solid in 83% yield from *N*-(2-Allyl-4-chlorophenyl)-4-methyl-benzenesulfonamide (**1e**)⁶ (57.4 mg, 0.178 mmol). mp = 108-110°C; $[\alpha]_D^{24} = 52.9^\circ$ (c = 0.5, CHCl₃), ee =87%, determined by HPLC analysis [Regis (*S*,*S*) Whelk-O 1, 2% IPA/hexane, 1 mL/min, $\lambda = 254$ nm, t(major) = 12.63 min, t(minor) = 14.73 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.58-7.55 (m, 3H), 7.23-7.18 (m, 3H), 7.04 (s, 1H), 4.37-4.31 (m, 1H), 3.64 (dd, J = 3.6, 10.0 Hz, 1H), 3.28 (apparent t, J = 9.6 Hz, 1H), 2.95-2.80 (m, 2H), 2.38 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 144.5, 139.9, 134.1, 132.3, 130.1, 129.9, 128.1, 127.0, 125.4, 117.7, 62.7, 34.7, 21.5, 11.0; IR (neat): 3029, 2924, 1598, 1473, 1357, 1167, 1023, 814, 666 cm⁻¹; HRMS (ESI) calcd for [M+Na]⁺ C₁₆H₁₅O₂NCIINaS 469.9449, found 469.9429.



(S)-2-(Iodomethyl)-5-methoxy-1-tosylindoline (4f)

Indoline **4f** (55.9 mg, 0.126 mmol) was obtained as a white solid in a 72% yield from the corresponding sulfonamide⁶ **1f** (55.7 mg, 0.175 mmol). mp = 137-139°C; $[\alpha]_D^{24} = 91.6$ ° (c = 0.5, CHCl₃), ee = 87%, determined by HPLC analysis [Regis (*S*,*S*) Whelk-O 1, 2% IPA/hexane, 1 mL/min, $\lambda = 254$ nm, t(major) = 22.87 min, t(minor) = 28.69 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.55 (d, J = 8.8 Hz, 1H), 7.51 (d, J = 8.4 Hz, 2H), 7.18 (d, J = 8.0 Hz, 2H), 6.76 (dd, J = 2.4, 8.8 Hz, 1H), 6.60 (d, J = 2.0 Hz, 1H), 4.33-4.31 (m, 1H), 3.76 (s, 3H), 3.62 (dd, J = 4.0, 10.0 Hz, 1H), 3.23 (apparent t, J = 9.6 Hz, 1H), 2.81-2.77 (m, 2H), 2.37 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 157.6, 144.1, 134.5, 134.2, 132.4, 129.7, 127.1, 118.2, 113.2, 110.9, 62.9, 55.6, 34.9, 21.5, 11.1; IR (neat): 3027, 2955, 1598, 1487, 1353, 1263, 1165, 1090, 1032, 813, 751, 667 cm⁻¹; HRMS (ESI) calcd for [M+1]⁺ C₁₇H₁₉O₃NIS 444.0125, found 444.0124.



(S)-2-(Iodomethyl)-6-methoxy-1-tosylindoline (4g)

Indoline **4g** (47.9 mg, 0.108 mmol) was obtained as a clear oil in a 71% yield from the corresponding sulfonamide⁴ **1g** (48.5 mg, 0.153 mmol). $[\alpha]_D^{24} = 80.3 \circ (c = 0.64, CHCl_3)$, ee = 88%, determined by HPLC analysis [Regis (*S*,*S*) Whelk-O 1, 2% IPA/hexane, 1 mL/min, $\lambda = 254$ nm, t(major) = 14.01 min, t(minor) = 18.02 min]; ¹H NMR (400 MHz, CDCl_3): δ 7.57 (d, J = 8.0 Hz, 2H), 7.23 (s, 1H), 7.19 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 8.0 Hz, 1H), 6.58 (dd, J = 2.4, 8.4 Hz, 1H), 4.38-4.30 (m, 1H), 3.82 (s, 3H), 3.64 (dd, J = 3.2, 10.0 Hz, 1H), 3.26 (apparent t, J = 10.0 Hz, 1H), 2.90-2.73 (m, 2H), 2.36 (s, 3H); ¹³C NMR (75.5 MHz, CDCl_3): δ 159.9, 144.3, 142.4, 134.6, 129.8, 127.1, 125.5, 122.1, 111.1, 102.7, 63.4, 55.7, 34.1, 21.6, 11.4; IR (neat): 3050, 2922, 1615, 1497, 1354, 1285, 1165, 1111, 1032, 812 cm⁻¹; HRMS (ESI) calcd for [M+Na]⁺ C₁₇H₁₈O₃NISNa 465.9944, found 465.9955.



2-(Iodomethyl)-7-methoxy-1-tosylindoline (4h)

Indoline **4h** (55.8 mg, 0.126 mmol) was obtained as opaque crystals in 80% yield from the corresponding sulfonamide **1h** (49.9 mg, 0.157 mmol). mp = 123-124°C; $[\alpha]_D^{24} = -4.7^\circ$ (c = 0.67, CHCl₃), ee = 15%, determined by HPLC analysis [Regis (*S*,*S*) Whelk-O 1, 2% IPA/hexane, 1 mL/min, λ = 254 nm, t(major) = 30.64 min, t(minor) = 36.97 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, J = 6.4 Hz, 2H), 7.22 (d, J = 6.0 Hz, 2H), 7.08 (t, J = 6.4 Hz, 1H), 6.81 (d, J = 6.4 Hz, 1H), 6.72 (d, J = 6.0 Hz, 1H), 4.80-4.76 (m,1H), 3.78 (s, 3H), 3.45 (dd, J = 3.6, 8.0 Hz, 1H), 3.11 (apparent t, J = 8.0 Hz, 1H), 2.73-2.71 (m, 2H), 2.40 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 151.9, 143.7, 136.2, 135.8, 129.9, 129.3, 127.44, 127.42, 117.6, 112.3, 64.3, 56.0, 34.6, 21.6, 9.6; IR (neat): 3027, 2925, 1595, 1488, 1333, 1277, 1158, 1088, 935, 813, 762, 675 cm⁻¹; HRMS (ESI) calcd for [M+1]⁺ C₁₇H₁₉O₃NIS 444.0125, found 444.0122.



(S)-2-(Iodomethyl)-1-(phenylsulfonyl)indoline (4i)

Indoline **4i** (53.2 mg, 0.133 mmol) was obtained as a white solid in a 77% yield from N-(2allylphenyl)benzene sulfonamide (**1i**) (47.2 mg, 0.173 mmol). mp = 82-84°C; $[\alpha]_D^{24}$ = 37.5° (c = 0.5, CHCl₃), ee = 88%, determined by HPLC analysis [Regis (*S*,*S*) Whelk-O 1, 2% IPA/hexane, 1 mL/min, λ = 254 nm, t(major) = 12.61 min, t(minor) = 14.74 min]; mp = 82-84°C; ¹H NMR (400 MHz, CDCl₃): δ 7.70-7.65 (m, 3H), 7.56-7.52 (m, 1H), 7.42-7.39 (m, 2H), 7.26-7.21 (m, 1H), 7.10-7.05 (m, 2H), 4.40-4.34 (m, 1H), 3.66 (dd, J = 3.2, 10.0 Hz, 1H), 3.26 (apparent t, J = 10.0 Hz, 1H), 2.92-2.82 (m, 2H); ¹³C NMR (75.5 MHz, CDCl₃): δ 141.0, 137.4, 133.3, 130.4, 129.1, 128.1, 127.0, 125.3, 125.0, 116.8, 62.6, 34.8, 11.2; IR (neat): 3067, 2921, 1596, 1479, 1357, 1169, 1091, 1016, 962, 756, 718, 688 cm⁻¹; HRMS (EI) calcd for [M]⁺ C₁₅H₁₄O₂NIS 398.9784, found 398.9781.



(S)-2-(Iodomethyl)-1-((4-nitrophenyl)sulfonyl)indoline (4j)

Indoline **4j** (57.2 mg, 0.129 mmol) was obtained as pale yellow crystals in 72% yield from the corresponding sulfonamide¹⁰ **1j** (57.0 mg, 0.179 mmol). For this reaction the (4*R*,5*S*)-di-Ph-box ligand was used and the catalyst/ligand loadings were doubled to 40 and 50 mol%, respectively. mp = 135-136°C; $[\alpha]_D^{24} = 87.8$ ° (c = 0.5, CHCl₃), ee = 80%, determined by HPLC analysis [Regis (*S*,*S*) Whelk-O 1, 2% IPA/hexane, 1 mL/min, $\lambda = 254$ nm, t(major) = 22.24 min, t(minor) = 25.38 min]; ¹H NMR (400 MHz, CDCl₃): δ 8.25 (d, J = 8.4 Hz, 2H), 7.88 (d, J = 9.6 Hz, 2H), 7.66 (d, J = 8.0 Hz, 1H), 7.27 (m, 1H), 7.10 (m, 2H), 4.41-4.35 (m,1H), 3.65 (dd, J = 3.6, 10.0 Hz, 1H), 3.29 (apparent t, J = 10.0 Hz, 1H), 3.00-2.85 (m, 2H); ¹³C NMR (75.5 MHz, CDCl₃): δ 150.5, 143.0, 140.1, 130.3, 128.4, 128.2, 125.7, 124.4, 116.6, 62.9, 34.8, 10.5; IR (neat): 3104, 2921, 1605, 1530, 1479, 1349, 1171, 1010, 855, 757, 620 cm⁻¹; HRMS (EI) calcd for [M]⁺ C₁₅H₁₃O₄N₂IS 443.9635, found 443.9641.



(S)-2-(Iodomethyl)-1-(methylsulfonyl)indoline (4k)

Indoline **4k** (54.6 mg, 0.162 mmol) was obtained as white crystals in 85% yield from *N*-(2-Allyl-phenyl)methyl-sulfonamide (**1k**)⁵ (38.0 mg, 0.180 mmol). For this reaction the (4*R*,5*S*)-di-Ph-box ligand (**3**) was used. mp = 163-165°C; $[\alpha]_D^{24}$ =-44.1° (c = 0.5, CHCl₃), ee = 81%, determined by HPLC analysis [Chiralpak AD-RH, 2% water/MeOH, 1 mL/min, λ = 254 nm, t(major) = 3.56 min, t(minor) = 5.12 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.42 (d, J = 8.0 Hz, 1H), 7.25-7.21 (m, 2H), 7.09 (t, J = 7.2 Hz, 2H), 4.43-4.46 (m, 1H), 3.63 (dd, J = 3.2, 9.6 Hz, 1H), 3.48 (dd, J = 10.0, 12.0 Hz, 1H), 3.31 (apparent t, J = 9.6 Hz, 1H), 3.05 (dd, J = 4.0, 16.8 Hz, 1H), 2.86 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 141.1, 129.5, 128.3, 125.5, 124.7, 115.1, 62.6, 36.3, 35.5, 11.6; IR (neat): 3009, 2924, 1479, 1344, 1157, 1018, 972, 770, 752 cm⁻¹; HRMS (EI) calcd for [M]⁺C₁₀H₁₂O₂NIS 336.9628, found 336.9628.



(S)-2-(Iodomethyl)-1-((2-(trimethylsilyl)ethyl)sulfonyl)indoline (4l)

Indoline **4I** (62.3 mg, 0.147 mmol) was obtained as a white solid in an 85% yield from *N*-(2-allylphenyl)-2-(trimethylsilyl)ethane sulfonamide (**1I**) (51.5 mg, 0.173 mmol). For this reaction the (4*R*,5*S*)-di-Ph-box ligand (**3**) was used. mp = 94-95°C; $[\alpha]_D^{24} = -32.2^\circ$ (c = 0.5, CHCl₃), ee = 82%, determined by HPLC analysis [Chiralpak AD-RH, 4% water/MeOH, 0.5 mL/min, $\lambda = 254$ nm, t(major) = 5.97 min, t(minor) = 7.07 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.35 (d, J = 7.6 Hz, 1H), 7.22-7.18 (m, 2H), 7.06 (t, J = 7.6 Hz, 1H), 4.56-4.52 (m, 1H), 3.61 (dd, J = 3.2, 10 Hz, 1H), 3.46 (dd, J = 9.6, 16.8 Hz, 1H), 3.28 (apparent t, J = 9.6 Hz, 1H), 3.07 (dd, J = 3.2, 16.4 Hz, 1H), 3.00-2.94 (m, 2H), 1.09-1.02 (m, 2H), -0.03 (s, 9H); ¹³C NMR (75.5 MHz, CDCl₃): δ 141.3, 129.1, 128.2, 125.5, 124.1, 114.4, 62.9, 46.8, 35.2, 11.8, 9.9, -2.1; IR (neat): 3010, 2950, 1603, 1479, 1348, 1252, 1149, 1105, 1023, 966, 841, 754 cm⁻¹; HRMS (ESI) calcd for [M+Na]⁺ C₁₄H₂₂O₂NINaSSi 446.0077, found 446.0078.



(S)-2-(Iodomethyl)-1-(3,5-ditertbutylbenzene sulfonyl)indoline (4m)

Indoline **4m** (64.2 mg, 0.126 mmol) was obtained as an orange solid in 90% yield from *N*-(2-allylphenyl)-3,5-di-*tert*-butylbenzenesulfonamide (**1m**) (53.8 mg, 0.140 mmol). mp = 126-127°C; $[\alpha]_D^{24}$ = 17.3° (c = 0.83, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 7.71 (d, J= 8.0 Hz, 1H), 7.54 (s, 1H), 7.42 (s, 2H), 7.26-7.22 (m, 1H), 7.07-7.03 (m, 2H), 4.32-4.25 (m, 1H), 3.62 (dd, J= 3.2, 9.6 Hz, 1H), 3.25 (t, J= 9.6 Hz, 1H), 2.81-2.67 (m, 2H), 1.20 (s, 18H); ¹³C NMR (75.5 MHz, CDCl₃): δ 152.1, 141.6, 136.4, 130.9, 127.9, 127.1, 125.1, 125.0, 121.1, 117.6, 62.7, 35.1, 34.7, 31.1, 11.1; IR (neat): 3031, 2961, 1598, 1478, 1360, 1248, 1170, 1012, 757 cm⁻¹; HRMS (ESI) calcd for [M+1]⁺ C₂₃H₃₁O₂NIS 512.1115, found 512.1112.

Procedure for the catalytic enantioselective aminochlorination of N-(2-allylphenyl)-4-methylbenzenesulfonamide:



(S)-2-(chloromethyl)-1-tosylindoline (4n)

Copper (II) triflate (12.6 mg, 0.035 mmol) was added to an oven-dried pressure tube (10 mL) equipped with a stir bar, in a glovebox. Upon removal from the glovebox the pressure tube was flushed with argon any time it was opened. To the tube, (R,R)-Ph-box (2) (14.5 mg, 0.043 mmol) in PhCF₃ (0.54 mL, 0.08 M) was added and the mixture was dissolved in additional PhCF₃ (1.20 mL), the tube was then sealed and heated to 60 °C for 2 h in an oil bath with stirring. The following reagents were then added sequentially: N-(2-allylphenyl)-4-methyl-benzenesulfonamide⁵ (51.8 mg, 0.180 mmol), MnO₂ (45.5 mg, 0.523 mmol), K₂CO₃ (24.8 mg, 0.179 mmol), 1,1-dichloroethylene (0.125 mL, 152.3 mg, 1.57 mmol) and ~35 mg of flame activated 4Å molecular sieves. The tube was then flushed with argon, sealed, and sonicated to ensure that all reagents were in solution. The mixture was stirred at 105 °C (oil bath) for 16 h. Upon cooling to rt and the mixture was filtered through a pad of Celite with EtOAc. The filtrate was collected and the solvent was removed *in vacou* to yield the crude product as a solid. Flash chromatography of the resulting crude material on SiO₂ (0-20% v/v EtOAc in hexanes gradient) afforded indoline 4n (37.7 mg, 0.117 mmol) as a white solid in 65% yield. Further purification by HPLC 10% EtOAc in hexanes, isocratic, was used prior to chiral HPLC analysis. mp = 140-141°C; $\left[\alpha\right]_{D}^{24} = 93.7^{\circ}$ (c = 0.63, CHCl₃), ee = 93%, determined by HPLC analysis [Regis (S,S) Whelk-O 1, 2% IPA/hexane, 1 mL/min, λ = 254 nm, t(major) = 12.35 min, t(minor) = 15.58 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.65 (d, J= 8.4 Hz, 1H), 7.56 (d, J= 8.4 Hz, 2H), 7.25-7.17 (m, 3H), 7.08-7.02 (m, 2H), 4.44-4.37 (m, 1H), 3.93 (dd, J= 3.6, 10.8 Hz, 1H), 3.55 (dd, J= 9.6, 10.4 Hz, 1H), 2.96-2.85 (m, 2H), 2.36 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 144.3, 141.1, 134.5, 130.7, 129.7, 127.9, 127.1, 125.3, 124.9, 116.9, 62.3, 46.9, 32.2, 21.6; IR (neat): 3031, 2923, 1598, 1480, 1355, 1168, 1092, 1035, 755 cm⁻¹; HRMS (ESI) calcd for [M+Na]⁺ C₁₆H₁₆O₂NCISNa 344.0482, found 344.0485.

Procedure for the catalytic enantioselective aminobromination of N-(2-allylphenyl)-4-methylbenzenesulfonamide:



(S)-2-(bromomethyl)-1-tosylindoline (40)

Copper (II) triflate (13.7 mg, 0.038 mmol) was added to an oven dried pressure tube (10 mL) equipped with a stir bar, in a glovebox. Upon removal from the glovebox the pressure tube was flushed with argon any time it was opened. To the tube, (R,R)-Ph-box (2) (15.8 mg, 0.047 mmol) in PhCF₃ (0.59 mL, 0.08 M) was added and the mixture was dissolved in additional PhCF₃ (1.30 mL), the tube was then sealed and heated to 60 °C for 2 h in an oil bath with stirring. The following reagents were then added sequentially: N-(2-allylphenyl)-4-methyl-benzenesulfonamide⁵ (55.3 mg, 0.192 mmol), MnO₂ (49.7 mg, 0.572 mmol), K₂CO₃ (26.1 mg, 0.189 mmol), (2,2-dibromo-1-methylcyclopropyl)benzene (0.185 mL, 329.5 mg, 1.14 mmol) and ~38 mg of flame activated 4Å molecular sieves. Once all reagents were added the tube was flushed with argon, sealed, and sonicated to ensure that all reagents were in solution, and placed in a pad of Celite with EtOAc. The filtrate was collected and the solvent was removed *in vacou* to yield the crude product as a solid. Flash chromatography of the resulting crude material on SiO₂ (0-20% v/v EtOAc in hexanes gradient) afforded indoline **40** (40.2 mg, 0.110 mmol) as a white solid in 57% yield. Further purification by HPLC 10% EtOAc in hexanes, isocratic, was used prior to chiral HPLC analysis:

mp = 98-99°C; $[\alpha]_D^{24} = 27.9^\circ$ (c = 0.79, CHCl₃), ee = 87%, determined by HPLC analysis [Regis (*S*,*S*) Whelk-O 1, 2% IPA/hexane, 1 mL/min, $\lambda = 254$ nm, t(major) = 13.25 min, t(minor) = 16.43 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.65 (d, J= 8.4 Hz, 1H), 7.57 (d, J= 8.4 Hz, 2H), 7.25-7.18 (m, 3H), 7.08-7.02 (m, 2H), 4.45-4.41 (m, 1H), 3.82 (dd, J= 3.6, 10.0 Hz, 1H), 3.41 (t, J= 10.4 Hz, 1H), 2.94-2.90 (m, 2H), 2.36 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 144.3, 141.1, 134.5, 130.6, 129.8, 127.9, 127.1, 125.3, 124.9, 116.9, 62.2, 35.9, 33.2, 21.6; IR (neat): 3031, 2923, 1598, 1479, 1355, 1168, 1092, 1026, 758 cm⁻¹; HRMS (ESI) calcd for [M+Na]⁺ C₁₆H₁₆O₂NBrSNa 387.9977, found 387.9986.

Procedure for the catalytic enantioselective aminohalogenation on a 0.5 g scale:



(S)-2-(Iodomethyl)-1-tosylindoline (4a)

Copper (II) triflate (125.2 mg, 0.346 mmol) was added to an oven dried pressure tube (60 mL) equipped with a stir bar, in a glovebox. Upon removal from the glovebox the pressure tube was flushed with argon any time it was opened. To the tube, (4R,5S)-di-Ph-box ligand (3) (211.4 mg, 0.434 mmol) was added and the mixture was dissolved in PhCF₃ (17.0 mL), the tube was then sealed and heated to 60 $^{\circ}$ C for 2 h in an oil bath with stirring. The following reagents were then added sequentially: N-(2-allylphenyl)-4methyl-benzenesulfonamide⁵ (504.6 mg, 1.756 mmol), MnO₂ (611.3 mg, 7.031 mmol), K₂CO₃ (242.8 mg, 1.757 mmol), ⁱPr-I (2.11 mL, 3.59 g, 21.1 mmol) and ~340 mg of flame activated 4Å molecular sieves. Once all reagents were added the tube was flushed with argon, sealed, and sonicated to ensure that all reagents were in solution. The reaction was then stirred at 105 °C (oil bath) for 24 h. The tube was then allowed to come to rt and the mixture was filtered through a pad of Celite with EtOAc. The filtrate was collected and the solvent was removed in vacou to yield the crude product as a solid. Flash chromatography of the resulting crude material on SiO₂ (0-20% v/v EtOAc in hexanes gradient) afforded the corresponding indoline 4a (537.0 mg, 1.30 mmol) in 74% yield and 88% ee. Further purification by HPLC 10% EtOAc in hexanes, isocratic, was used prior to chiral HPLC analysis. The ee was further enriched to >98% via recrystalization from CH₂Cl₂/hexanes.

Procedure for the catalytic enantioselective aminohalogenation of 1d on a 0.25 g scale:



(S)-5-Fluoro-2-(iodomethyl)-1-tosylindoline (4d)

Copper (II) triflate (59.7 mg, 0.165 mmol) was added to an oven dried pressure tube (40 mL) equipped with a stir bar, in a glovebox. Upon removal from the glovebox the pressure tube was flushed with argon any time it was opened. To the tube, (4*R*,5*S*)-di -Ph-box ligand (**3**) (100.7 mg, 0.207 mmol) was added and the mixture was dissolved in PhCF₃ (8.2 mL), the tube was then sealed and heated to 60 °C for 2 h in an oil bath with stirring. The following reagents were then added sequentially: *N*-(2-Allyl-4-fluoro-phenyl)-4-methyl-benzenesulfonamide (**1d**)⁶ (252.5 mg, 0.827 mmol), MnO₂ (216.3 mg, 2.488 mmol), K₂CO₃ (114.3 mg, 0.827 mmol), ⁱPr-I (0.75 mL, 1.28 g, 7.50 mmol) and ~164 mg of flame activated 4Å molecular sieves. Once all reagents were added the tube was flushed with argon, sealed, and sonicated to ensure that all reagents were in solution. The reaction was then stirred at 105 °C (oil bath) for 6 h. The tube was then allowed to come to rt and the mixture was filtered through a pad of Celite with EtOAc. The filtrate was collected and the solvent was removed *in vacou* to yield the crude product as a solid. Flash chromatography of the resulting crude material on SiO₂ (0-20% v/v EtOAc in hexanes gradient)

afforded the corresponding indoline **4d** (267.0 mg, 0.619 mmol) in 75% yield and 92% ee. Further purification by HPLC 10% EtOAc in hexanes, isocratic, was used prior to chiral HPLC analysis.

Catalytic Methods for 4-Pentenyl Sulfonamide Substrates:



(S)-2-(Iodomethyl)-4,4-dimethyl-1-tosylpyrrolidine (8a) (Representative procedure)

Copper (II) triflate (13.9 mg, 0.039 mmol) was added to an oven dried pressure tube (10 mL) equipped with a stir bar, in a glovebox. Upon removal from the glovebox the pressure tube was flushed with argon any time it was opened. To the tube, (4R,5S)-di-Ph-box ligand (3) (21.0 mg, 0.043 mmol) was added and the mixture was dissolved in PhCF₃ (1.73 mL), the tube was then sealed and heated to 60 °C for 2 h in an oil bath with stirring. The following reagents were then added sequentially: *N*-(2, 2-dimethyl-pent-4-enyl)-4-methyl-benzenesulfonamide (**7a**)¹²(51.5 mg, 0.193 mmol), MnO₂ (45.1 mg, 0.518 mmol), K₂CO₃ (23.9 mg, 0.173 mmol), ⁱPr-I (0.103 mL, 175.1 mg, 1.03 mmol) and ~35 mg of flame activated 4Å molecular sieves. Once all reagents were added the tube was flushed with argon, sealed, and sonicated to ensure that all reagents were in solution. The reaction was then stirred at 105 °C (oil bath) for 11 h. The tube was then allowed to come to rt and the mixture was filtered through a pad of Celite with EtOAcc. The filtrate was collected and the solvent was removed *in vacou* to yield the crude product as a solid. Flash chromatography of the resulting crude material on SiO₂ (0-20% v/v EtOAc in hexanes gradient) afforded the corresponding pyrrolidine **8a** in 81% yield. Further purification using HPLC (10% EtOAc in hexanes, isocratic) was performed prior to chiral HPLC analysis.

Pyrrolidine **8a** (61.3 mg, 0.156 mmol) was obtained as an oil in 81% yield from *N*-(2, 2-dimethyl-pent-4enyl)-4-methyl-benzenesulfonamide (**7a**)¹²(51.5 mg, 0.193 mmol): mp = 65-67 °C; $[\alpha]_D^{24}$ = -110.0 ° (c = 0.5, CHCl₃), ee = 88%, determined by HPLC analysis [Chiralpak AD-RH, 4% IPA/hexane, 1 mL/min, λ = 254 nm, t(major) = 7.34 min, t(minor) = 8.61 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.74 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 3.77 (dd, J = 2.8, 9.2 Hz, 1H), 3.74-3.65 (m, 1H), 3.37 (apparent t, J = 8.8 Hz, 2H), 2.44 (s, 3H), 1.92 (dd, J = 7.6, 12.8 Hz, 1H), 1.60 (dd, J = 8.4, 12.8 Hz, 1H), 1.05 (s, 3H), 0.51 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 143.7, 134.9, 129.7, 127.5, 62.0, 60.1, 47.8, 37.5, 26.0, 25.8, 21.5, 13.2; IR (neat): 3029, 2958, 1598, 1465, 1347, 1157, 1092, 816, 662 cm⁻¹; HRMS (ESI) calcd for [M+1]⁺C₁₄H₂₁O₂NIS 394.0332, found 394.0336.



(S)-2-(Iodomethyl)-4,4-dimethyl-1-(methylsulfonyl)pyrrolidine (8b)

Pyrrolidine **8b** (49.8 mg, 0.157 mmol) was obtained as a white solid in a 78% yield from the corresponding sulfonamide¹⁶ **7b** (38.5 mg, 0.201 mmol): mp = 79-80°C; $[\alpha]_D^{24} = -16.7^\circ$ (c = 0.5, CHCl₃), ee = 43%, determined by HPLC analysis [Chiralpak AD-RH, 2% water/MeOH, 1 mL/min, $\lambda = 254$ nm, t(minor) = 3.57 min, t(major) = 4.09 min]; ¹H NMR (400 MHz, CDCl₃): δ 3.88-3.82 (m, 1H), 3.55-3.47 (m, 2H), 3.24 (ABq, J_{AB} = 10.0 Hz, $\Delta v = 60.4$ Hz, 2H), 2.95 (s, 3H), 2.04-1.98 (m, 1H), 1.70-1.64 (m, 1H), 1.14 (s, 3H), 1.09 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 61.4, 59.4, 47.3, 39.4, 38.0, 26.5, 25.7, 13.7; IR (neat): 2958, 1466, 1331, 1148, 1050, 963 cm⁻¹; HRMS (ESI) calcd for [M+Na]⁺C₈H₁₆O₂NISNa 339.9839, found 339.9847.



(S)-2-(Iodomethyl)-4,4-dimethyl-1-((4-nitrophenyl)sulfonyl)pyrrolidine (8c)

Pyrrolidine **8c** (61.7 mg, 0.146 mmol) was obtained as pale yellow crystals in a 80% yield from *N*-(2, 2-dimethyl-pent-4-enyl)-4-nitro-benzenesulfonamide (**7c**)¹⁷(54.4 mg, 0.182 mmol), the reaction time was increased to 24 h for this reaction: mp = 93-95°C; $[\alpha]_D^{24} = -51.1^\circ$ (c = 1.00, CHCl₃), ee = 60%, determined by HPLC analysis [Chiralpak AD-RH, 2% IPA/Hex , 1 mL/min, λ = 254 nm, t(major) = 15.27 min, t(minor) = 20.06 min]; ¹H NMR (400 MHz, CDCl₃): δ 8.38 (d, J = 12.8 Hz, 2H), 8.05 (d, J = 12.0 Hz, 2H), 3.81-3.75 (m, 1H), 3.65 (dd, J = 2.8, 10.0 Hz, 1H), 3.44 (dd, J = 8.0 Hz, 9.6 Hz, 1H), 3.28-3.20 (m, 2H), 1.95 (dd, J = 7.2, 12.8 Hz, 1H), 1.65 (dd, J = 8.4, 12.8 Hz, 1H), 1.08 (s, 3H), 0.63 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 150.1, 144.3, 128.5, 124.4, 61.9, 60.2, 47.4, 37.9, 26.0, 25.6, 12.7; IR (neat): 3104, 2960, 2875, 1605, 1530, 1349, 1161, 1091, 856, 743, 615 cm⁻¹; HRMS (ESI) calcd for [M-I]⁺ C₁₃H₁₇O₄N₂S 297.0900, found 297.1000.



(S)-2-(Iodomethyl)-4,4-diphenyl-1-tosylpyrrolidine (8d)

Pyrrolidine **8d** (75.9 mg, 0.147 mmol) was obtained as white crystals in 85% yield from *N*-(2, 2-diphenyl-pent-4-enyl)-4-methyl-benzenesulfonamide (**7d**)¹⁴(67.6 mg, 0.173 mmol): mp = 78-80°C; $[\alpha]_D^{24} = 6.7^\circ$ (c = 0.5, CHCl₃), ee = 93%, determined by HPLC analysis [Chiralpak AD-RH, 2% IPA/hexane, 0.5 mL/min, $\lambda = 254$ nm, t(minor) = 29.47 min, t(major) = 31.39 min]; ¹H NMR (500 MHz, CDCl₃): δ 7.60 (d, J = 8.0 Hz, 2H), 7.30-7.07 (m, 12H), 4.43 (d, J = 10.0 Hz, 1H), 3.88-3.84 (m, 1H), 3.75 (d, J = 10.0 Hz, 1H), 3.67 (dd, J = 3.0, 9.5 Hz, 1H), 2.85-2.78 (m, 2H), 2.66 (dd, J = 5.0, 13.0 Hz, 1H), 2.40 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 144.6, 144.4, 143.6, 134.0, 129.8, 128.7, 128.6, 127.4, 126.8, 126.6, 126.5, 126.3, 60.4, 59.2, 52.2, 43.8, 21.5, 11.3; IR (neat): 3026, 2962, 1598, 1495, 1448, 1344, 1262, 1162, 1091, 1029, 813, 753, 701, 665 cm⁻¹; HRMS (ESI) calcd for [M+1]⁺C₂₄H₂₅O₂NIS 518.0645, found 518.0658.



(S)-2-(Iodomethyl)-1-tosylpyrrolidine (8e)

Pyrrolidine **8e** (49.7 mg, 0.136 mmol) was obtained as a white solid in a 77% yield from *N*-(pent-4-enyl)-4-methyl-benzenesulfonamide (**7e**)⁵(42.3 mg, 0.177 mmol): mp = 89-91°C; $[\alpha]_D^{24} = -103.2^\circ$ (c = 0.5, CHCl₃), ee = 73%, determined by HPLC analysis [Chiralpak AD-RH, 2% IPA/hexane, 1 mL/min, $\lambda = 254$ nm, t(major) = 10.85 min, t(minor) = 12.73 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.73 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 3.77-3.72 (m, 1H), 3.62 (dd, J = 2.8, 9.6 Hz, 1H), 3.51-3.47 (m, 1H), 3.253.16 (m, 2H), 2.44 (s, 3H), 1.91-1.80 (m, 3H), 1.56-1.50 (m, 1H); ¹³C NMR (75.5 MHz, CDCl₃): δ 143.8, 134.2, 129.8, 127.5, 60.7, 50.1, 32.0, 23.8, 21.6, 11.5; IR (neat): 3027, 2971, 1597, 1448, 1346, 1159, 1092, 986, 816, 665 cm⁻¹; HRMS (EI) calcd for [M]⁺C₁₂H₁₆O₂NIS 364.9941, found 364.9952.



(S)-1-((3,5-Di-*tert*-butylphenyl)sulfonyl)-2-(iodomethyl)pyrrolidine (8f)

Pyrrolidine **8f** (58.3 mg, 0.126 mmol) was obtained as white crystals in 85% yield from the corresponding sulfonamide **7f**(50.0 mg, 0.148 mmol): mp = 94-95°C; $[\alpha]_D^{24}$ = -63.8° (c = 1.00, CHCl₃), ee = 82%, determined by HPLC analysis [Regis (*S*,*S*) Whelk-O 1, 2% IPA/hexane, 1.0 mL/min, λ = 254 nm, t(major) = 9.30 min, t(minor) = 10.59 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.66-7.64 (m, 3H), 3.78-3.71 (m, 1H), 3.61 (dd, J = 2.8, 9.6 Hz, 1H), 3.49-3.44 (m, 1H), 3.27-3.17 (m, 2H), 1.89-1.81 (m, 3H), 1.55-1.50 (m, 1H), 1.36 (s, 18H); ¹³C NMR (75.5 MHz, CDCl₃): δ 152.3, 136.7, 126.9, 121.6, 60.7, 50.0, 35.1, 32.1, 31.3, 39.9, 23.9, 11.7; IR (neat): 3067, 2963, 1599, 1476, 1348, 1248, 1164, 1114, 1024, 985, 789 cm⁻¹; HRMS (ESI) calcd for [M+Na]⁺C₁₉H₃₀O₂NISNa 486.0934, found 486.0935.



(S)-8,8-Di-*tert*-butyl-3-(iodomethyl)-2-tosyl-7,9-dioxa-2-aza-8-silaspiro[4.5]decane (8g)

Pyrrolidine **8g** (35.0 mg, 0.062 mmol) was obtained as white crystals in 78% yield from the corresponding sulfonamide **7g**⁴ (34.9 mg, 0.079 mmol): mp = 123-125°C; $[\alpha]_D^{24} = -25.6^\circ$ (c = 0.23, CHCl₃), ee = 92%, determined by HPLC analysis [Regis (*S*,*S*) Whelk-O 1, 4% IPA/hexane, 1.0 mL/min, $\lambda = 254$ nm, t(major) = 15.77 min, t(minor) = 18.98 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.73 (d, J = 8.0 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 3.94 (ABq, J_{AB} = 10.8, $\Delta v = 42.3$ Hz, 2H), 3.73-3.38 (m, 2H), 3.33 (ABq, J_{AB} = 11.6, $\Delta v = 165.4$ Hz, 2H), 3.40-3.33 (m, 2H), 2.46 (s, 3H), 1.96 (dd, J = 7.6, 14 Hz, 1H), 1.53 (dd, J = 7.6, 14 Hz, 1H), 1.02 (s, 18H); ¹³C NMR (75.5 MHz, CDCl₃): δ 144.1, 134.1, 129.9, 127.5, 71.6, 69.7, 59.1, 56.1, 45.3, 39.9, 29.7, 28.0, 27.5, 22.6, 21.6, 21.2, 12.9; IR (neat): 3010, 2928, 1599, 1471, 1348, 1160, 1064, 909, 824, 764 cm⁻¹; HRMS (ESI) calcd for [M+1]⁺ C₂₂H₃₇O₄NISSi 566.1252, found 566.1267.

Assignment of Absolute Stereochemistry of Pyrrolidine Products:

The crystal structure of pyrrolidine 8g (CCDC 858585) showing the S stereochemistry was obtained by William W. Brennessel at the University of Rochester. The absolute configuration of all other pyrrolidine products was assigned by analogy to this structure.



(S)-2-(Iodomethyl)-3,3-dimethyl-1-tosylpyrrolidine (10)

Pyrrolidine **10** (52.5 mg, 0.134 mmol) was obtained as a white solid in a 78% yield from *N*-(3,3dimethylpent-4-enyl)-4-methylbenzenesulfonamide (**9**)¹⁹(45.8 mg, 0.171 mmol): mp = 61-63°C; $[\alpha]_D^{24}$ = -67.1° (c = 0.5, CHCl₃), ee = 82%, determined by HPLC analysis [Chiralpak AD-RH, 2% IPA/hexane, 1 mL/min, λ = 254 nm, t(major) = 9.21 min, t(minor) = 10.69 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.75 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 3.51-3.33 (m, 4H), 3.13-3.08 (m, 1H), 2.44 (s, 3H), 2.03-1.98 (m, 1H), 1.35-1.31 (m, 1H), 1.16 (s, 3H), 0.52 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 143.7, 134.1, 129.6, 127.6, 67.7, 46.3, 42.1, 37.6, 28.5, 22.8, 21.6, 7.8; IR (neat): 3031, 2962, 1598, 1466, 1345, 1163, 1094, 1050, 816, 665 cm⁻¹; HRMS (EI) calcd for [M]⁺C₁₄H₂₀O₂NIS 393.0254, found 393.0244.



(S)-2-(Iodomethyl)-2,4,4-trimethyl-1-tosylpyrrolidine (12)

Pyrrolidine **12** (52.1 mg, 0.128 mmol) was obtained as a yellow oil in a 74% yield from *N*-(2,2,4-trimethyl-pent-4-enyl)- 4-methyl-benzenesulfonamide (**11**)¹⁵(48.8 mg, 0.173 mmol): $[\alpha]_D^{24} = 7.2^\circ$ (c = 0.67, CHCl₃), ee = 16%, determined by HPLC analysis [Chiralpak AD-RH, 2% IPA/hexane, 1 mL/min, $\lambda = 254$ nm, t(major) = 7.56 min, t(minor) = 8.98 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.75 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 3.74 (ABq, J_{AB} = 10.0 Hz, $\Delta v = 72.3$ Hz, 2H), 3.17 (ABq, J_{AB} = 9.2 Hz, $\Delta v = 39.1$ Hz, 2H), 2.43 (s, 3H), 1.90 (ABq, J_{AB} = 12.8 Hz, $\Delta v = 186.6$ Hz, 2H), 1.71 (s, 3H), 1.08 (s, 3H), 0.96 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 143.1, 137.7, 129.5, 127.4, 67.3, 62.1, 55.3, 36.1, 27.4, 27.1, 25.9, 21.5, 19.8; IR (neat): 3027, 2957, 1598, 1448, 1338, 1212, 1155, 1092, 1044, 970, 815, 713, 659 cm⁻¹; HRMS (EI) calcd for [M]⁺C₁₅H₂₂O₂NIS 407.0410, found 407.0403.



(S)-3-(Iodomethyl)-2-tosyl-1,2,3,4-tetrahydroisoquinoline (14)

Tetrahydroisoquinoline **14** (54.6 mg, 0.128 mmol) was obtained as a yellow oil in a 73% yield from *N*-(2-allylbenzyl)-4-methylbenzenesulfonamide (**13**)⁵(52.8 mg, 0.175 mmol). The (*R*,*R*)-Ph-box ligand (**2**) was used for this reaction: $[\alpha]_D^{24} = 29.2^\circ$ (c = 0.37, CHCl₃), ee = 27%, determined by HPLC analysis [Regis (*S*,*S*) Whelk-O 1, 4% IPA/hexane, 1 mL/min, $\lambda = 254$ nm, t(major) = 28.09 min, t(minor) = 34.05 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.70 (d, J = 8.0 Hz, 2H), 7.27-7.25 (m, 2H), 7.18-7.16 (m, 2H), 7.10-7.05 (m, 2H), 4.39 (ABq, J_{AB} = 15.6 Hz, $\Delta v = 21.3$ Hz, 2H), 4.34-4.31 (m, 1H), 3.28 (dd, J = 3.6, 6.0 Hz, 1H), 3.08 (dd, J = 3.2, 16.0 Hz, 1H), 2.96 (apparent t, J = 10.4 Hz, 1H), 2.82 (dd, J = 5.2, 12.8 Hz, 1H), 2.40 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 143.7, 135.8, 131.9, 131.8, 129.8, 129.1, 127.5, 127.3, 126.8, 126.1, 53.8, 44.5, 31.9, 21.5, 7.4; IR (neat): 3027, 2922, 1598, 1495, 1456, 1335, 1161, 1091, 1038, 907, 814, 745, 664 cm⁻¹; HRMS (ESI) calcd for [M+1]⁺ C₁₇H₁₉O₂NIS 428.0176, found 428.0169. The absolute stereochemistry of **14** was assigned by analogy to **8e**.

Assignment of Relative Stereochemistry of Pyrrolidine Product 16:



(3aR,5S,6aR)-3a-allyl-5-(iodomethyl)-1-tosyloctahydrocyclopenta[b]pyrrole (16)

Pyrrolidine **16** (52.6 mg, 0.118 mol) was obtained as a clear oil in a 70% yield from the corresponding sulfonamide **15** (53.9 mg, 0.169 mmol). The stereochemistry of H_C was assigned by analogy to crystal structure **8g**. An nOe experiment showing a strong signal between the allyl methylene protons and H_C was used to assign the stereochemistry of the quaternary carbon center, this experiment also showed a strong signal between the allyl methylene protons and H_A. The stereochemistry of the last chiral center was assigned based on an nOe experiment showing a strong signal between H_A and H_F : $[\alpha]_D^{24} = -25.5^{\circ}$ (c = 0.5, CHCl₃), ee = 91%, determined by HPLC analysis [Chiralpak AD-RH, 2% water/MeOH, 1 mL/min, $\lambda = 254$ nm, t(major) = 4.70 min, t(minor) = 6.75 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.70 (d, J = 10.0 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 5.43-5.36 (m, 1H), 4.90 (d, J = 12.0 Hz, 1H), 4.82 (d, J = 18.8 Hz, 1H) 3.49-3.41 (m, 2H), 3.43-3.23 (m, 1H), 3.16-3.12 (m, 1H), 2.99-2.92 (m, 1H), 2.45 (s, 3H), 2.39-2.32 (m, 2H), 1.86 (dd, J = 3.2, 7.6 Hz, 2H), 1.74-1.62 (m, 3H), 1.47-1.43 (m, 1H), 1.18 (dd, J = 11.2, 12.8 Hz,

1H); ¹³C NMR (75.5 MHz, CDCl₃): δ 143.6, 133.8, 133.2, 129.6, 127.9, 118.4, 69.3, 54.2, 48.9, 45.0, 43.8, 41.2, 40.1, 36.0, 21.5, 11.1; IR (neat): 3070, 2948, 1639, 1598, 1451, 1344, 1162, 1093, 919, 816, 657 cm⁻¹; HRMS (ESI) calcd for [M+1]⁺C₁₈H₂₅O₂NIS 446.0645, found 446.0638.

Substitution and Cross-Coupling Reactions:



(S)-2-(Azidomethyl)-5-fluoro-1-tosylindoline (17)

To an oven dried flask with a stir bar, under argon, was added (*S*)-5-fluoro-2-(iodomethyl)-1-tosylindoline (**4d**) (44.8 mg, 0.104 mmol, 92% ee), sodium azide (20.5 mg, 0.315 mmol) and 1.05 mL of DMF. The flask was then allowed to stir under an inert atmosphere at room temperature for 24 h. The reaction mixture was then filtered through a pad of Celite with ethyl acetate. The filtrate was collected and the solvent removed *in vacuo* providing 79.1 mg of crude material. The crude product was further purified via flash chromatography on SiO₂ (0-30% EtOAc in hexanes eluent) providing pure alkyl azide **17** (35.3 mg, 0.102 mmol) as white crystals in 98% yield: mp = 98-99 °C; $[\alpha]_D^{24} = 144.2^\circ$ (c = 0.85, CHCl₃), ee = 92%, determined by HPLC analysis [Regis (*S*,S) Whelk-O 1, 2% IPA/hexane, 1.0 mL/min, $\lambda = 254$ nm, t(major) = 20.71 min, t(minor) = 24.96 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.62 (dd, J = 4.8, 8.4 Hz, 1H), 7.51 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 8.4 Hz, 2H), 6.95 (td, J = 2.4, 8.8 Hz, 1H), 6.76 (dd, J = 2.8, 8.0 Hz, 1H), 4.39-4.29 (m, 1H), 3.60-3.50 (m, 2H), 2.80-2.65 (m, 2H), 2.37 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 160.6 (d, J = 244.2 Hz), 144.4, 137.3, 134.2, 133.5 (d, J = 8.1 Hz), 129.8, 127.1, 118.5 (d, J = 8.1 Hz), 114.6 (d, J = 24.2 Hz), 112.3 (d, J = 24.2 Hz), 61.5, 55.2, 32.1, 21.6; IR (neat): 3030, 2924, 1599, 1482, 1356, 1166, 1091, 893, 815 cm⁻¹; HRMS (ESI) calcd for [M+Na]⁺ C₁₆H₁₅O₂N₄FSNa 369.0792, found 369.0799.



(S)-5-Fluoro-2-(phenylthiomethyl)-1-tosylindoline (18)

To an oven dried flask with a stir bar, under argon, was added (S)-5-fluoro-2-(iodomethyl)-1tosylindoline (4d) (44.1 mg, 0.102 mmol, 92% ee), thiophenol (31 μ L, 33.4 mg, 0.303 mmol), K₂CO₃ (14.5 mg, 0.105 mmol) and 1.00 mL of DMF. The flask was then allowed to stir under an inert atmosphere at room temperature for 24 h. The reaction mixture was then filtered through a pad of Celite with ethyl acetate, the filtrate was collected and the solvent removed in vacuo providing 146.4 mg of crude material. The crude product was further purified via flash chromatography on SiO₂ (0-30% EtOAc in hexanes eluent). Indoline **18** (41.3 mg, 0.100 mmol) was obtained as a clear oil in 98% yield: $[\alpha]_D^{24} = -$ 15.5° (c = 0.57, CHCl₃), ee = 92%, determined by HPLC analysis [Chiralpak AD-RH, 2% IPA/hexane, 1.0 mL/min, $\lambda = 254$ nm, t(major) = 21.11 min, t(minor) = 14.21 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.59 (dd, J = 4.8, 8.4 Hz, 1H), 7.44 (d, J = 7.6 Hz, 2H), 7.39-7.34 (m, 4H), 7.27-7.23 (m, 1H), 7.11 (d, J = 8.0 Hz, 2H), 6.91 (td, J = 2.4, 9.2 Hz, 1H), 6.74 (dd, J = 2.8, 8.0 Hz, 1H), 4.30-4.22 (m, 1H), 3.67 (dd, J = 3.6, 13.6 Hz, 1H), 2.92-2.73 (m, 3H), 2.34 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 160.4 (d, J = 243.2 Hz), 144.1, 137.2 (d, J = 2.3 Hz), 134.7, 134.2, 133.3 (d, J = 9.2 Hz), 129.6, 129.1 (d, J = 2.3 Hz), 126.9, 126.3, 118.2 (d, J = 8.1 Hz), 114.5 (d, J = 24.2 Hz), 112.4 (d, J = 24.2 Hz), 61.2, 38.5, 33.2, 21.5; IR (neat): 3058, 2923, 1599, 1482, 1356, 1166, 1090, 1026, 935, 814 cm⁻¹; HRMS (ESI) calcd for [M+Na]⁺ C₂₂H₂₀O₂NFS₂Na 436.0812, found 436.0812.



(*R*)-2-Benzyl-5-fluoro-1-tosylindoline (19) was prepared by a procedure analogous to that developed by Cahiez.²²

To an oven dried flask with a stir bar, under argon, was added Fe(acac)₃ (5.8 mg, 0.016 mmol), HMTA (2.6 mg, 0.019 mmol), TMEDA (5 μL, 3.9 mg, 0.033 mmol,), (S)-5-fluoro-2-(iodomethyl)-1tosylindoline (4d) (48.6 mg, 0.113 mmol, 92% ee) and 0.145 mL of THF. The reaction was then stirred and cooled to -5 °C over the course of a few minutes. Once the mixture had cooled, 1.2M phenyl magnesium bromide (0.203 mL, 0.276 mmol) was added dropwise over an hour. Once the addition was complete the reaction was allowed to stir for an additional 30 minutes before being guenched with aqueous HCl 1M (1.0 mL). The mixture was then extracted with Et_2O (3 x 1.5 mL), the organics were combined and the solvent removed *in vacuo* providing 77.6 mg of crude material. The crude product was further purified via flash chromatography on SiO_2 (0-20% EtOAc in hexanes eluent) to provide indoline **20** (34.4 mg, 0.090 mmol) as white crystals in 80% yield: mp = 99-100°C; $[\alpha]_D^{24} = 39.1^\circ$ (c = 0.78, CHCl₃), ee = 90%, determined by HPLC analysis [Chiralpak AD-RH, 8% IPA/hexane, 1.0 mL/min, λ = 254 nm, t(major) = 10.91 min, t(minor) = 6.12 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.61 (dd, J = 4.8, 9.2 Hz, 1H), 7.53 (d, J = 8.4 Hz, 2H), 7.32-7.21 (m, 5H), 7.16 (d, J = 8.0 Hz, 2H), 6.91 (td, J = 2.0, 8.4 Hz, 2H), 7.16 (d, J = 8.0 Hz, 2H), 6.91 (td, J = 2.0, 8.4 Hz, 2H), 7.16 (d, J = 8.0 Hz, 2H), 7.16 1H), 6.69 (dd, J = 1.6, 7.6 Hz, 1H), 4.49-4.43 (m, 1H), 3.30 (dd, J = 4.4, 13.6 Hz, 1H), 2.79 (dd, J = 10.0, 13.2 Hz, 1H), 2.53 (d, J = 6.0 Hz, 2H), 2.35 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 160.3 (d, J = 243.2 Hz), 143.9, 137.4, 137.3, 136.9, 134.9, 134.1 (d, J = 9.2 Hz), 129.6, 128.5, 126.9, 126.7, 118.6 (d, J = 8.1 Hz), 114.3 (d, J = 23.1 Hz), 112.4 (d, J = 24.2 Hz), 63.9, 42.4, 32.8, 21.5; IR (neat): 3029, 2922, 1599, 1481, 1354, 1165, 1090, 1031, 814 cm⁻¹; HRMS (ESI) calcd for $[M+Na]^+ C_{22}H_{20}O_2NFSNa$ 404.1091, found 404.1095.



0.5 g scale:









0.25 g scale with the (4R, 5S)-di-Ph-box ligand:


















































References:

- (1) Masamune, S.; Lowenthal, R. Patent # US19910789748 19911108 1994.
- (2) Denmark, S. E., Stiff, C. J. Org. Chem. 2000, 65, 5875-5878.
- (3) Huntress, E. H.; Carten, F. H. J. Am. Chem. Soc. 1940, 62, 511-514.
- (4) Fuller, P. H.; Kim, J.-W.; Chemler, S. R. J. Am. Chem. Soc. 2008, 130, 17638-17639.
- (5) Hegedus, L. S. M. J. M. J. Am. Chem. Soc. 1982, 104, 2444-2451.
- (6) Yin, Y.; Z., G. J. Fluor. Chem. 2007, 128, 40-45.
- (7) Muniz, K.; Hovelmann, C. H.; Streuff, J. J. Am. Chem. Soc. 2008, 130, 763-773.
- (8) Bennasar, M. L. R., T.; Monerris, M.; Garcia-Diaz, D. J. J. Org. Chem. 2006, 71, 7028-7034.
- (9) Lira, R.; Wolfe, J. P. J. Am. Chem. Soc. 2004, 126, 13906-13907.
- (10) Sherman, E. S.; Chemler, S. R.; Tan, T. B.; Gerlits, O. Org. Lett. 2004, 6, 1573-1575.
- (11) El Ali, B.; Okuro, K.; Vasapollo, G.; Alper, H. J. Am. Chem. Soc. 1996, 118, 4264-4270.
- (12) Michael, F. E. C., B. M. J. Am. Chem. Soc. 2006, 128, 4246-4247.
- (13) Bender, C. F. W., R. A. J. Am. Chem. Soc. 2005, 127, 1070-1071.
- (14) Zhang, J. Y.; C.-G.; He, C. J. Am. Chem. Soc. 2006, 128, 1798-1799.
- (15) Tamaru, Y. H., M.; Higashimura, H.; Yoshida, Z.-I. J. Am. Chem. Soc. **1988**, 110, 3994-4002.
- (16) de Haro, T.; Nevado, C. Angew. Chem., Int. Ed. 2011, 50, 906-910.
- (17) Sherman, E. S.; Fuller, P. H.; Kasi, D.; Chemler, S. R. J. Org. Chem. 2007, 72, 3896-3905.
- (18) Miao, L.; Haque, I.; Manzoni, M. R.; Tham, W. S.; Chemler, S. R. Org. Lett. 2011, 12, 4739-4741.
- (19) Haque, I. Master's dissertation, University at Buffalo, 2009.
- (20) Marcotullio, M. C.; Campagna, V.; Sternativo, S.; Costantino, F.; Curini, M. Synthesis **2006**, 2760-2766.
- (21) Flemer, S.; Madalengoitia, J. S. Synthesis 2007, 1848-1860.
- (22)Cahiez, G.; Habiak, V.; Duplais, C.; Moyeux, A. Angew. Chem., Int. Ed. 2007, 46, 4364-4366.
















































-0.511

0.077

ppm

2.91





Sample Name: Data Collected on: Chemnmr400.chem.buffalo.edu-inova400 Archive directory: Sample directory: FidFile: PROTON Pulse Sequence: PROTON (s2pul) Solvent: cdcl3 Data collected on: Aug 13 2010 Temp. 25.0 C / 298.1 K Dperator: Chemler Jperator: Chemier Relax. delay 1.000 sec Pulse 45.0 degrees Acq. time 2.565 sec Width 6387.7 Hz 8 repetitions DSERVE H1, 339.5389035 MHz DATA PROCESSING F1 size 32768 Fotal time 0 min 29 sec 8c 8.396 8.394 8.382 8.387 8.387 8.435 8.065 8.056 8.056 8.056 8.054 8.053 8.034 8.035 8.034 8.035 8.0555 8.0555 8.0555 8.0555 8.0555 8.0555 8.0555 8.0555 8 Ňs 3.637 -3.631 3.464 -3.444 -3.446 -3.440 -3.276 3.250 -3.204 -3.795 -3.792 -3.769 -3.766 -3.766 -3.662 -3.655 8.403 7 5 8 6 4 ż ب ب 1.96 2.00 لب ب ب ب 0.98 1.03 0.98 2.08 Sample Name: 71.430 Data Collected on: roesy.chem.buffalo.edu-mercury300 Archive directory: Sample directory: FidFile: CARBON Pulse Sequence: CARBON (s2pul) Solvent: cdcl3 Data collected on: Aug 12 2010 Operator: Chemler

1.938 -1.669 -1.669 -1.648 -1.637 -1.637 -1.51 -1.551 -1.254 1.078

 $\begin{array}{c} 2.042 \\ -2.040 \\ 1.970 \\ 1.952 \end{array}$

ź

ب ب 0.99 1.01 0.629

-1.047

1

ب 2.88 ų

2.93

ppm

 Operator: Chemier

 Paixe: dis 0 degrees

 Paixe: dis 0, 75 Mg

 DBSERVE (13, 75, 658.855 MHZ

 DBSERVE (13, 75, 658.857 MHZ

 DBSERVE (13, 759.757 MHZ

 DBSERVE (13, 759.757 MHZ

140 120 100 80 60 40 20 ppm











Sample Name: Data Collected on: chemnar400.chee.buffalo.edu-inova400 Archive directory: Sample directory: Fidfile: HTB-1-26 Pulse Sequence: PROTON (s2pul) Solvent: cdc33 Data collected on: Dec 2 2011

Temp. 25.0 C / 298.1 K Operator: Chemler

Operator: Chemier Relax. delay 1.000 sec Pulse 45.0 degrees Acq. time 2.555 sec Width 6387.7 Hz 6 repetitos 05357VE H1.059.8380027 MHz 05357VE H1.059.8380027 MHz 053570F 11.0527680 Total time 0 min 29 sec















